Vanrafia (atrasentan) / Chinook Therap, AbbVie, Novartis 
Welcome,         Profile    Billing    Logout  

12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vanrafia (atrasentan) / Novartis
2020-003084-26: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)

Completed
3
384
Europe, RoW
atrasentan, [Atrasentan], Film-coated tablet
Chinook Therapeutics U.S., Inc., CHINOOK THERAPEUTICS, U.S., Inc, Chinook Therapeutics U.S., Inc.
Immunoglobulin A Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN), Diseases [C] - Immune System Diseases [C20]
 
 
ALIGN, NCT04573478 / 2024-513227-16-00 / 2020-003084-26: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc., Chinook Therapeutics U.S., Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT07498335: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Not yet recruiting
3
28
NA
Drug: Atrasentan
Novartis Pharmaceuticals
Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
11/30
01/31
CEXV811A12301, 2024-513227-16-00`2020-003084-26: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)

Active, not recruiting
2/3
42
Europe
Placebo - Film coated tablet for oral use, atrasentan
Novartis Pharma AG, Chinook Therapeutics U.S., Inc.
Immunoglobulin A Nephropathy (IgAN)
 
 
2020-004176-18: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) Estudio de fase 2, abierto, “en cesta”, de atrasentán en pacientes con enfermedades glomerulares proteinúricas (estudio AFFINITY)

Ongoing
2
80
Europe
atrasentan, [atrasentan], Film-coated tablet
Chinook Therapeutics U.S., Inc., CHINOOK THERAPEUTICS, U.S., Inc, Chinook Therapeutics U.S., Inc.
Proteinuric glomerular diseases, including:Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g)Focal segmental glomerulosclerosis (FSGS)Alport SyndromeDiabetes kidney disease (DKD) (as add-on to RAS and sodium glucose co-transporter 2 [SGLT2] inhibitors) Enfermedades glomerulares proteinúricas, que incluyen:Nefropatía por inmunoglobulina A (NIgA) (con UPCR de 0,5 a <1,0 g / g)Glomeruloesclerosis focal y segmentaria (GEFS)Síndrome de AlportNefropatía diabética (ND) (como complemento de los inhibidores del cotransportador 2 [SGLT2] de glucosa y sodio RAS), Proteinuric glomerular diseases:Immunoglobulin A nephropathy (IgAN) Focal segmental glomerulosclerosis (FSGS)Alport SyndromeDiabetes kidney disease (DKD) Enfermedades glomerulares proteinúricas:Nefropatía por inmunoglobulina A (NIgA)Glomeruloesclerosis focal y segmentaria (GEFS)Síndrome de AlportNefropatía diabética (ND), Diseases [C] - Immune System Diseases [C20]
 
 
ASSIST, NCT06841094: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Active, not recruiting
2
54
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Novartis Pharmaceuticals
IgA Nephropathy, Immunoglobulin A Nephropathy
10/25
08/26
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
10/26
ASSIST, NCT05834738 / 2023-503828-13-00: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Completed
2
54
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
IgA Nephropathy, Immunoglobulin A Nephropathy
06/25
10/25
ASSIST, 2023-503828-13-00: A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2i

Completed
1/2
10
Europe
Matching placebo film-coated round tablets, atrasentan, DAPAGLIFLOZIN
Novartis Pharma AG, Novartis Pharma AG
Nephrology
 
 
NCT07319585: Managed Access Programs for EXV811, Atrasentan

Available
N/A
NA
Atrasentan, EXV811
Novartis Pharmaceuticals
IgA Nephropathy
 
 
NCT06952426: A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Recruiting
N/A
300
US
No intervention, Other treatment, Iptacopan, Atrasentan
Novartis Pharmaceuticals
Immunoglobulin A Nephropathy
06/25
06/25
NCT07481084: IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection

Not yet recruiting
N/A
80
NA
Novartis Pharmaceuticals
IgA Nephropathy
03/29
03/29

Download Options